Clinical Trials Browser

Hyperthermia, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fever, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Neuroendocrine Tumors

NCT06134271 2023-11-18

RASTOM

Phase 2 Not yet recruiting

160 enrolled

Genitourinary

Prostatic Neoplasms

NCT06129851 2023-11-13

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

Phase 2 Not yet recruiting

90 enrolled

Genitourinary

Prostatic Neoplasms

NCT05717582 2023-02-08

CHAMPION

Phase 2 Not yet recruiting

47 enrolled

Genitourinary

Prostatic Neoplasms

NCT05373316 2022-11-07

AFFIRM

Phase 2 Not yet recruiting

95 enrolled

Genitourinary

Prostatic Neoplasms

NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Phase 2 Not yet recruiting

200 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04925063 2021-06-14

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

Phase 2 Not yet recruiting

266 enrolled

Genitourinary

Prostatic Neoplasms

NCT04622761 2021-01-05

CHROME

Phase 2 Not yet recruiting

120 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

ANDARP

TeLuNa

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Patients With Recurrent Prostate Cancer After Prostatectomy

Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

ARPEGGIO

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

TerbinaPro

SENTRY

AxeCan

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

FORWARD

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

CONVERT-HB1

Memantine Hydrochloride in Prostate Cancer Patients

Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy

Folate Study in Men With Advanced Prostate Cancer

POSTPONE

TOPPGUN-RS

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Immunotherapy Before and After Surgery

Cleaning the Biopsy Needle in TRUS Bx

Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients with Intermediate or High Risk Localized Prostate Cancer (ARP)

The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy

Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.

ESTRACISE

SChLAP/IDC

HETERERO

RASTOM

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

CHAMPION

AFFIRM

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

CHROME